Boulder BioSciences wants to share some of the scientific articles that we base our hypothesis on for designing formulations for different indications. Since we are limited in what we may claim for our products by the FDA, we like to be able to refer our customers and their physicians to these articles so that they may make a more educated decision. Some of our clients are physicians and this section may help them in reviewing the literature for potential uses of CBD & CBDA and recommended doses.
- Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs
- The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
- Joints for joints: cannabinoids in the treatment of rheumatoid arthritis
- Cannabinoids, inflammation, and fibrosis
- Transdermal cannabidiol reduces inflammation and pain-related behaviors in a rat model of arthritis
- Cannabidiol induces programmed cell death in breast cancer cells by coordinating the crosstalk between apoptosis and autophagy
- Cannabidiol as potential anticancer drug
- Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration
- The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis
- COX-2 and PPAR-γ Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells
- The current state and future perspectives of cannabinoids in cancer biology
- Cannabinoid Delivery System for Pain and Inflammation Treatment
- Standardized Methods for the Determination of Antioxidant Capacity and Phenolics in Foods and Dietary Supplements
- An Update on Safety and Side Effects of Cannabidiol: A review of Clinical Data and Relevant Animal Studies
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trail of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
- Cannabinoids and Epilepsy
- Regulation of nausea and vomiting by cannabinoids
- Human Cannabinoid Pharmacokinetics
- Pot is Hot – What You Need to Know: Cannabinoid-pharmaceutical Interactions
- Practical considerations in medical cannabis administration and dosing.
- The effects of Delta9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbance in rat colitis
- Plasma Cannabinoid Pharmacokinetics following Controlled Oral Delta9-Tetrahydrocannabinoil and Oromucosal Cannabis Extract Administration
- Cannabidiol in Humans—The Quest for Therapeutic Targets
- CANNABIDIOL (CBD) Pre-Review Report Agenda Item 5.2 WHO
- The Therapeutic Potential of Cannabis and Cannabinoids
- Fatty Acid-binding Proteins (FABPs) Are Intracellular Carriers for ⌬9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
- Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
- The Endocannabinoid System and its Modulation by Phytocannabinoids
- Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects
- Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
- Cannabidiol (CBD) and its analogs: A review of their effects on inflammation
- Cannabidiol: State of the art and new challenges for therapeutic applications
- COX-2-derived endocannabinoid metabolites as novel inflammatory mediators
- Safety and Side Effects of Cannabidiol, a Cannabis sativa constituent
- Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents
- Isolation of Delta9-THCA-A from hemp and analytical aspects concerning the determination of Delta9-THC in cannabis products
- Phytocannabinoids: a unified critical inventory
- Long-term Storage and Cannabis Oil Stability
- Decarboxylation
- Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa.
- Cannabinoids as novel anti-inflammatory drugs
- Cannabinoid delivery systems for pain and inflammation treatment.
- Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation
- Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress
- Cannabidiol (CBD) and its analogs: a review of their effects on inflammation
- NSAIDs Dare to Compare
- An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs
- Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation
- The effects of Δ 9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.
- An orally active Cannabis extract with high content in cannabidiol attenuates chemically-induced intestinal inflammation and hypermotility in the mouse
- Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
- Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability
- Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Expermintal Allergic Autoimmune Encephalomyelitis: A model of Multiple Sclerosis
- Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice
- A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis
- A study of GPR3, GPR6, of GPR12 as novel molecular targets for cannabidiol.
- Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain
- Recent data on cannabinoids and their pharmacological implications in neuropathic pain
- Cannabidiol and (-) 9-tetrahydrocannabinol are neuroprotective antioxidants
- Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain
- Cannabidiol, neuroprotection and neuropsychiatric disorders
- Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors
- Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
- Symptom-relieving and neroprotective effects of the phytocannabinoid Delta9-THCV in animal models of Parkinson’s disease
- Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle
- Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- Does cannabidiol protect against adverse psychological effects of THC?
- The Endocannabinoid System and Cannabidiol’s Promise for the Treatment of Substance Use Disorder
- Therapeutical use of the cannabinoids in psychiatry
- Eicosanoid storm in infection and inflammation
- The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis
- The Endocannabinoid System as an Emerging Target of Pharmacotherapy
- Genetics and the placebo effect: the placebome
- Prostaglandins and Inflammation
- Endocannabinoids: A unique opportunity to develop multitarget analgesics